› Forums › General Melanoma Community › Array BioPharma Announces Withdrawal of NDA for Binimetinib Monotherapy for the Treatment of NRAS-Mutant Melanoma
- This topic has 1 reply, 1 voice, and was last updated 7 years, 1 month ago by AshleyS.
- Post
-
- March 24, 2017 at 5:52 pm
I have been following Array and the progress on binimetinib.
Looks like NRAS patients won't have a solution in MEK162 / Binimetinib since Array has withdrawn the NDA for the NRAS specific treatment that showed positive results after results of NEMO trial concluded last year.
Passing this along. Hope all of you are doing GREAT – and if you aren't – know that you are in my prayers.
See below link:
https://www.drugs.com/nda/binimetinib_170319.html
Best,
Neil D
- Replies
-
-
- March 27, 2017 at 5:28 pm
Hi Neil,
I had agreed to testify on behalf of Array for this drug. Although I am doing well, I wanted to help other fighters with the NRAS mutation. It was also in the back of my mind that someday I would need the struggle for myself. I remember when I was first diagnosed and found out I did not have the BRAF gene; initially I was sad because I realized I did not qualify for many drugs. Hopefully we will hear more about this in the future.
Ashley
-
- You must be logged in to reply to this topic.